-
1Academic Journal
Συγγραφείς: Karine O. Avetisyan, Nikolay N. Murashkin, Svetlana G. Makarova, Svetlana S. Petrichuk, Daria G. Kuptsova, К. О. Аветисян, Н. Н. Мурашкин, С. Г. Макарова, С. С. Петричук, Д. Г. Купцова
Συνεισφορές: Not specified, Отсутствует
Πηγή: Current Pediatrics; Том 22, № 5 (2023); 415-424 ; Вопросы современной педиатрии; Том 22, № 5 (2023); 415-424 ; 1682-5535 ; 1682-5527
Θεματικοί όροι: регуляторные Т-клетки, children, epidermal barrier, cell-mediated immunity, activated T-helpers, Th17-lymphocytes, Treg-cells, дети, эпидермальный барьер, клеточный иммунитет, активированные T-хелперы, Th17-лимфоциты
Περιγραφή αρχείου: application/pdf; application/msword
Relation: https://vsp.spr-journal.ru/jour/article/view/3303/1323; https://vsp.spr-journal.ru/jour/article/view/3303/1334; Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009. J Am Acad Dermatol. 2010;63(4):607–641. doi: https://doi.org/10.1016/j.jaad.2009.11.020; Richard G. Autosomal Recessive Congenital Ichthyosis. 2001 Jan 10 [Updated 2023 Apr 20]. In: GeneReviews® [Internet]. Adam MP, Mirzaa GM, Pagon RA, et al., eds. Seattle (WA): University of Washington, Seattle; 1993–2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK1420. Accessed on October 19, 2023.; Мурашкин Н.Н., Аветисян К.О., Иванов Р.А., Макарова C.Г. Врожденный ихтиоз: клинико-генетические характеристики заболевания // Вопросы современной педиатрии. — 2022. — Т. 21. — № 5. — С. 362–377. — doi: https://doi.org/10.15690/vsp.v21i5.2459; Sun Q, Burgren NM, Cheraghlou S, et al. The Genomic and Phenotypic Landscape of Ichthyosis: An Analysis of 1000 Kindreds. JAMA Dermatol. 2022;158(1):16–25. doi: https://doi.org/10.1001/jamadermatol.2021.4242; Ихтиоз у детей: клинические рекомендации. — Союз педиатров России; 2016. — С. 6.; Lee AY. Molecular Mechanism of Epidermal Barrier Dysfunction as Primary Abnormalities. Int J Mol Sci. 2020;21(4):1194. doi: https://doi.org/10.3390/ijms21041194; Malik K, He H, Huynh TN, et al. Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature. J Allergy Clin Immunol. 2019;143(2):604–618. doi: https://doi.org/10.1016/j.jaci.2018.03.021; Кондратенко И.В., Бологов А.А. Первичные иммунодефициты: учебное пособие. — М.: ИндексМед Медиа; 2020. — С. 31.; Czarnowicki T, He H, Leonard A, et al. The Major Orphan Forms of Ichthyosis Are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc-22 Polarization in Blood. J Invest Dermatol. 2018;138(10):2157–2167. doi: https://doi.org/10.1016/j.jid.2018.03.1523; Paller AS, Renert-Yuval Y, Suprun M, et al. An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. J Allergy Clin Immunol. 2017;139(1):152–165. doi: https://doi.org/10.1016/j.jaci.2016.07.019; Mazereeuw-Hautier J, Vahlquist A, Traupe H, et al. Management of congenital ichthyoses: European guidelines of care, part one. Br J Dermatol. 2019;180(2):272–281. doi: https://doi.org/10.1111/bjd.17203; Mazereeuw-Hautier J, Hernández-Martín A, O’Toole EA, et al. Management of congenital ichthyoses: European guidelines of care, part two. Br J Dermatol. 2019;180(3):484–495. doi: https://doi.org/10.1111/bjd.16882; Youssefian L, Vahidnezhad H, Saeidian AH, et al. Autosomal recessive congenital ichthyosis: Genomic landscape and phenotypic spectrum in a cohort of 125 consanguineous families. Hum Mutat. 2019;40(3):288–298. doi: https://doi.org/10.1002/humu.23695; Sabat R, Wolk K, Loyal L, et al. T cell pathology in skin inflammation. Semin Immunopathol. 2019;41(3):359–377. doi: https://doi.org/10.1007/s00281-019-00742-7; Купцова Д.Г., Радыгина Т.В., Курбатова О.В. и др. Содержание субпопуляций CD4+T-клеток в прогнозе эффективности биологической терапии псориаза у детей // Медицинская иммунология. — 2023. — Т. 25. — № 5. — С. 1071–1078. — doi: https://doi.org/10.15789/1563-0625-COC-2704; Mansouri Y, Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. J Clin Med. 2015;4(5):858–873. doi: https://doi.org/10.3390/jcm4050858; Мурашкин Н.Н., Опрятин Л.А., Епишев Р.В. и др. Новая эра в лечении атопического дерматита: результаты длительного применения дупилумаба // Вопросы современной педиатрии. — 2021. — Т. 20. — № 5. — С. 390–395. — doi: https://doi.org/10.15690/vsp.v20i5.2312; Купцова Д.Г., Петричук С.В., Мурашкин Н.Н. и др. Ранние предикторы эффективности биологической терапии псориаза у детей // Аллергология и иммунология в педиатрии. 2023. — № 1. — С. 49–52. — doi: https://doi.org/10.53529/2500-11752023-1-49-52; Tausend W, Downing C, Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg. 2014;18(3):156–169. doi: https://doi.org/10.2310/7750.2013.13125; Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi: https://doi.org/10.1016/j.jaad.2018.11.057; Wollenberg A, Thomsen SF, Lacour JP, et al. Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence. World Allergy Organ J. 2021;14(3):100519. doi: https://doi.org/10.1016/j.waojou.2021.100519; Agache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelinesdupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021;76(4):988–1009. doi: https://doi.org/10.1111/all.14690; Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. doi: https://doi.org/10.1111/all.13954; Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. doi: https://doi.org/10.1016/s0140-6736(21)00184-7; Briot A, Deraison C, Lacroix M, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med. 2009;206(5):1135–1147. doi: https://doi.org/10.1084/jem.20082242; Reche PA, Soumelis V, Gorman DM, et al. Human thymic stromal lymphopoietin preferentially stimulates myeloid cells. J Immunol. 2001;167(1):336–343. doi: https://doi.org/10.4049/jimmunol.167.1.336; Fontao L, Laffitte E, Briot A, et al. Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J Invest Dermatol. 2011;131(9):1947–1950. doi: https://doi.org/10.1038/jid.2011.124; Кондратенко И.В., Бологов А.А. Первичные иммунодефициты: учебное пособие. — М.: ИндексМед Медиа; 2020. — С. 117–120.; Eränkö E, Ilander M, Tuomiranta M, et al. Immune cell phenotype and functional defects in Netherton syndrome. Orphanet J Rare Dis. 2018;13(1):213. doi: https://doi.org/10.1186/s13023-018-0956-6; Hannula-Jouppi K, Laasanen SL, Ilander M, et al. Intrafamily and Interfamilial Phenotype Variation and Immature Immunity in Patients With Netherton Syndrome and Finnish SPINK5 Founder Mutation. JAMA Dermatol. 2016;152(4):435–442. doi: https://doi.org/10.1001/jamadermatol.2015.5827; Paller AS. Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses. J Invest Dermatol. 2019;139(3): 535–540. doi: https://doi.org/10.1016/j.jid.2018.08.027; Paller AS, Czarnowicki T, Renert-Yuval Y, et al. The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab. J Am Acad Dermatol. 2018;78(3):498–505.e2. doi: https://doi.org/10.1016/j.jaad.2017.10.026; Luchsinger I, Knöpfel N, Theiler M, et al. Secukinumab Therapy for Netherton Syndrome. JAMA Dermatol. 2020;156(8):907–911. doi: https://doi.org/10.1001/jamadermatol.2020.1019; Yogarajah J, Gouveia C, Iype J, et al. Efficacy and safety of secukinumab for the treatment of severe ABCA12 deficiencyrelated ichthyosis in a child. Skin Health Dis. 2021;1(2):e25. doi: https://doi.org/10.1002/ski2.25